Janssen has recently announced its intention to close its Psoriasis 360 facebook page.
Note: the ‘clause 2’ referred to below makes reference to Clause 2 of the ABPI’s Code of Practice for the Pharmaceutical Industry (2012 PDF) and those activities deemed to bring ‘discredit to, and reduction of confidence in, the industry.’ (p. 8)
@pmlivecom a shame for #pharma #hcsmeu visionaries, but as Facebook currently don’t have a ‘vertical’ for pharma is it a surprise?
@teammjl IMO, point is that at launch P360 fb page was actively directed/modded, but has been left to stagnate for months recently #hcsmeu
@andrewspong agreed, & brings into play exit strategy debate and sadly for me, gives credence to ye olde resource/A/E reporting concern?
@teammjl Why wd a pharma company *want* an exit strategy for conveying info via the world’s #2 Internet site? What’d be better? #hcsmeu
@andrewspong the burning question? Show commercial returns that outweigh compliance implications (Cost of a clause 2 or audit process inclu)
What do you make of Janssen’s decision?